HK1246190A1 - 長效g-csf綴合物的液體製劑 - Google Patents

長效g-csf綴合物的液體製劑

Info

Publication number
HK1246190A1
HK1246190A1 HK18105764.3A HK18105764A HK1246190A1 HK 1246190 A1 HK1246190 A1 HK 1246190A1 HK 18105764 A HK18105764 A HK 18105764A HK 1246190 A1 HK1246190 A1 HK 1246190A1
Authority
HK
Hong Kong
Prior art keywords
acting
long
liquid formulation
csf conjugate
csf
Prior art date
Application number
HK18105764.3A
Other languages
English (en)
Inventor
李美枝
李才敏
李炳善
裴城敏
權世昌
Original Assignee
韓美科學株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44307381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1246190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 韓美科學株式會社 filed Critical 韓美科學株式會社
Publication of HK1246190A1 publication Critical patent/HK1246190A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18105764.3A 2010-01-19 2018-05-04 長效g-csf綴合物的液體製劑 HK1246190A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100004839 2010-01-19

Publications (1)

Publication Number Publication Date
HK1246190A1 true HK1246190A1 (zh) 2018-09-07

Family

ID=44307381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105764.3A HK1246190A1 (zh) 2010-01-19 2018-05-04 長效g-csf綴合物的液體製劑

Country Status (17)

Country Link
US (1) US9867777B2 (zh)
EP (1) EP2525787B1 (zh)
JP (2) JP5657698B2 (zh)
KR (1) KR101340710B1 (zh)
CN (2) CN107412737A (zh)
AR (1) AR080427A1 (zh)
AU (1) AU2011207915B2 (zh)
BR (1) BR112012017979B1 (zh)
CA (1) CA2787648C (zh)
ES (1) ES2654102T3 (zh)
HK (1) HK1246190A1 (zh)
HU (1) HUE034398T2 (zh)
MX (1) MX340463B (zh)
PT (1) PT2525787T (zh)
RU (1) RU2519031C1 (zh)
TW (1) TWI409082B (zh)
WO (1) WO2011090305A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340463B (es) 2010-01-19 2016-07-06 Hanmi Science Co Ltd * Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
WO2012059882A2 (en) * 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
DK2945745T3 (da) * 2013-01-19 2022-04-25 Fluicell Ab Fremgangsmåder til fremstilling, ændring, fjernelse og anvendelse af væskemembraner
WO2014142102A1 (ja) * 2013-03-12 2014-09-18 大日本住友製薬株式会社 液体水性組成物
JP6521959B2 (ja) 2013-07-31 2019-05-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲート
EA201691795A1 (ru) * 2014-03-31 2017-03-31 Ханми Фарм. Ко., Лтд. Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
WO2015162563A1 (en) 2014-04-25 2015-10-29 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
CN107949307B (zh) 2015-09-14 2020-09-01 大王制纸株式会社 纸管和使用该纸管的卷状片材
CN105311625A (zh) * 2015-11-23 2016-02-10 哈药集团生物工程有限公司 一种含有重组人粒细胞刺激因子的药物组合物
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
EP3694535A4 (en) * 2017-10-11 2021-07-28 Elanco US Inc. VARIANTS OF PORCINE G-CSF AND THEIR USES
WO2019212429A2 (en) * 2018-05-04 2019-11-07 İlkogen İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable hybrid fc fusion g-csf formulation
DK3923973T3 (da) * 2019-02-13 2023-04-24 Ilkogen Ilac Sanayi Ve Ticaret A S Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni
DK3744319T3 (da) * 2019-05-28 2023-01-16 Ilkogen Ilac Sanayi Ve Ticaret A S Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910005624B1 (ko) 1985-09-17 1991-08-01 쥬우가이 세이야꾸 가부시끼가이샤 인체 과립성 백혈구의 콜로니 자극 인자 활성을 갖는 당단백질의 제조방법
IE63992B1 (en) 1985-09-17 1995-06-28 Chugai Pharmaceutical Co Ltd Human granulocyte colony stimulating factor
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
EP0789776B1 (en) 1994-11-01 2001-06-13 Winfried Wels Nucleic acid transfer system
WO1997012977A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR19990009888A (ko) 1997-07-12 1999-02-05 성재갑 콜로니 자극 인자의 안정한 용액 제형
AU749815B2 (en) 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
JP4454571B2 (ja) * 1998-03-06 2010-04-21 中外製薬株式会社 蛋白非添加製剤
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
EP1869078A2 (en) 2005-03-17 2007-12-26 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
KR20060108040A (ko) 2005-04-12 2006-10-17 주식회사 엘지생명과학 인 과립구 콜로니 자극인자 용액 제형
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
AU2008275180A1 (en) 2007-07-10 2009-01-15 Eli Lilly And Company GLP-1-Fc fusion protein formulation
EA020069B1 (ru) 2007-08-27 2014-08-29 Биодженерикс Аг Жидкая лекарственная форма конъюгата
WO2009113148A1 (ja) 2008-03-10 2009-09-17 Dic株式会社 鉄錯体を触媒とする重合体の製造方法
MX340463B (es) 2010-01-19 2016-07-06 Hanmi Science Co Ltd * Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법

Also Published As

Publication number Publication date
MX340463B (es) 2016-07-06
JP5657698B2 (ja) 2015-01-21
BR112012017979A2 (pt) 2016-05-03
HUE034398T2 (en) 2018-02-28
CA2787648A1 (en) 2011-07-28
WO2011090305A3 (en) 2011-11-10
EP2525787A2 (en) 2012-11-28
US20120294829A1 (en) 2012-11-22
CN102740840A (zh) 2012-10-17
CN107412737A (zh) 2017-12-01
KR20110085917A (ko) 2011-07-27
AU2011207915B2 (en) 2013-07-11
AU2011207915A1 (en) 2012-08-23
EP2525787A4 (en) 2014-07-02
US9867777B2 (en) 2018-01-16
TWI409082B (zh) 2013-09-21
JP2013517324A (ja) 2013-05-16
WO2011090305A2 (en) 2011-07-28
TW201129387A (en) 2011-09-01
KR101340710B1 (ko) 2013-12-12
MX2012008454A (es) 2012-11-06
JP2014224151A (ja) 2014-12-04
EP2525787B1 (en) 2017-03-15
BR112012017979B1 (pt) 2021-10-13
RU2519031C1 (ru) 2014-06-10
CA2787648C (en) 2014-10-07
AR080427A1 (es) 2012-04-11
PT2525787T (pt) 2017-12-18
ES2654102T3 (es) 2018-02-12

Similar Documents

Publication Publication Date Title
HK1246190A1 (zh) 長效g-csf綴合物的液體製劑
IL251318A0 (en) Long-acting preparations containing insulin
HK1207816A1 (zh) 長效胰島素綴合物的液體製劑
HK1204921A1 (zh) 依那西普的穩定液體製劑
IL224225B (en) Liquid formulation of long-acting human growth hormone conjugate
ZA201301717B (en) Liquid agricultural formulations of improved stability
EP2525779A4 (en) LIQUID FORMULATIONS FOR A ERYTHROPOIETIN CONJUGATE WITH LONG-TERM EFFECT
GB2481881B (en) Liquid formulations
PL2575501T3 (pl) Trwały płynny preparat wysokolipidowy
GB201121476D0 (en) Novel pharmaceutical formulation
HUE049344T2 (hu) Gyermekgyógyászati készítmény
GB201014317D0 (en) Preparation of electrode compositions
GB201013871D0 (en) Liquid formulations
GB201008873D0 (en) Liquid formulations